Where it trades today
trading 17% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- GEHC trades at 14.8x earnings versus 22.0x for the sector, which means the rerating case depends on proving the discount is too harsh.
- GEHC carries a beta of 0.82, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
- GEHC remains in a bearish short-term trend and sits 28.6% below its high, which raises the bar for any thesis that depends on fast multiple expansion.
Portfolio Use Case
- GEHC is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A recovery in price alone would not be enough to improve the view; the thesis needs confirmation from improving business or valuation signals.
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for GEHC come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for GEHC. Last refresh: Sep 18, 2026, 10:56 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What GE HealthCare does
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis,…
What analysts expect
GEHC carries a buy consensus from 18 analysts, with an average price target of $82.50 versus $64.13 today (+28.6%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
GEHC generated $21.27B in trailing revenue (5.8% year over year), with a 9.3% net margin, and $1.57B of free cash flow, against $8.46B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $20.63B | $8.25B | $2.76B | $2.08B | $4.56 | $1.50B |
| 2024 | $19.67B | $8.21B | $2.63B | $1.99B | $4.37 | $1.55B |
| 2023 | $19.55B | $7.92B | $2.44B | $1.57B | $3.05 | $1.71B |
| 2022 | $18.34B | $7.18B | $2.52B | $1.92B | $4.63 | $1.80B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
GEHC beside the healthcare names it is usually measured against.
What the chart is saying
GE HealthCare trades at $64.13, 28.6% below its 52-week high. With a beta of 0.82, it shows about average sensitivity to what the wider market does.
Questions people ask about it
Is GEHC a good buy right now?
GE HealthCare trades at 14.8x earnings. This is below market average, potentially undervalued. Current risk level is Medium based on 19.1% volatility.
Does GEHC pay dividends?
Yes, GE HealthCare offers a dividend yield of 0.22%. That is roughly $0.14 per share a year.
How volatile is GEHC?
With 30-day annualized volatility of 19.1% and beta of 0.82, GEHC is classified as Medium risk. The stock tends to be more stable than the market average.
What is the analyst price target for GEHC?
The average analyst price target for GE HealthCare (GEHC) is $82.50 based on 18 analyst estimates, about 28.6% above the current price of $64.13. The published range runs from $70.00 to $96.00.
How much revenue does GEHC generate?
GE HealthCare reported $21.27B in trailing twelve-month revenue. Revenue growth is running at 5.8% year over year. Net margin sits at 9.3%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.